Can functional logic beat genetic drift? MindWalk’s bet on influenza physics
MindWalk says flu can’t mutate past this. Find out how its HYFT AI platform found a functional constraint that may redefine universal vaccine design.
Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.
Can Kinaset’s inhaled JAK inhibitor finally bring relief to all severe asthma patients?
Kinaset raises $103M to advance frevecitinib, a novel inhaled JAK inhibitor for severe asthma. Find out what makes this candidate different.
Ollin’s next-gen VEGF/Ang2 antibody shows superiority over faricimab in Phase 1b trial
Ollin’s OLN324 outperformed faricimab in a head-to-head retinal trial. Find out how this could change first-line treatment in DME and wAMD.
Can SonoThera’s RIPPLE platform redefine nonviral delivery in oversized genetic payloads?
Can SonoThera’s ultrasound platform reshape gene therapy delivery? Find out how its $125M Series B targets DMD, ADPKD, and XLAS with nonviral precision.
Will Surf’s SUSTAIN platform bring at-home neuromodulation to mainstream rheumatology?
Surf begins human trial for ultrasound-based neuromodulation in RA. Can it challenge biologics? Find out what this means for autoimmune therapy access.
Why Aetna’s pediatric telehealth play with Blueberry could redefine Medicaid access
Can Aetna’s new pediatric telehealth model with Blueberry cut ER visits and scale Medicaid care? Find out what this pilot means for future access.
Can Enodia’s SEC61-targeting platform redefine druggability in secreted and membrane proteins?
Enodia Therapeutics raised €20.7M to advance AI-powered small molecules targeting SEC61 for selective protein degradation. Find out what this could change.
ENYO Pharma’s vonafexor reverses kidney decline in Alport syndrome with sustained benefit
Vonafexor reversed kidney decline in Alport syndrome patients. Find out what ENYO Pharma’s Phase 2 results could mean for FXR drugs and kidney care.
Can Alessa’s Enolen implant change how early-stage prostate cancer is treated?
Alessa’s Enolen earns FDA fast track for localized prostate cancer. Find out how this implant could redefine early-stage treatment and challenge current norms.